메뉴 건너뛰기




Volumn 2014, Issue 2, 2014, Pages

Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; EDOXABAN; RIVAROXABAN; THROMBIN INHIBITOR; XIMELAGATRAN;

EID: 85041496114     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010956     Document Type: Article
Times cited : (41)

References (43)
  • 1
    • 84856784474 scopus 로고    scopus 로고
    • Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    • Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G, American College of Chest Physicians. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(Suppl 2):e44S-88S.
    • (2012) Chest , vol.141 , pp. e44S-e88S
    • Ageno, W.1    Gallus, A.S.2    Wittkowsky, A.3    Crowther, M.4    Hylek, E.M.5    Palareti, G.6
  • 2
    • 34447317298 scopus 로고    scopus 로고
    • Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study
    • Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 2007;116(2):180-7.
    • (2007) Circulation , vol.116 , Issue.2 , pp. 180-187
    • Agnelli, G.1    Gallus, A.2    Goldhaber, S.Z.3    Haas, S.4    Huisman, M.V.5    Hull, R.D.6
  • 4
    • 55549147508 scopus 로고    scopus 로고
    • Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases
    • Baetz BE, Spinler SA. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 2008;28(11):1354-73.
    • (2008) Pharmacotherapy , vol.28 , Issue.11 , pp. 1354-1373
    • Baetz, B.E.1    Spinler, S.A.2
  • 5
    • 84856798208 scopus 로고    scopus 로고
    • Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    • Bates SM, Jaeschke R, Stevens SM, Goodacre S, Wells P, Stevenson MD, et al. Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e351S-418S.
    • (2012) Chest , vol.141 , Issue.2 , pp. e351S-e418S
    • Bates, S.M.1    Jaeschke, R.2    Stevens, S.M.3    Goodacre, S.4    Wells, P.5    Stevenson, M.D.6
  • 6
    • 47649098524 scopus 로고    scopus 로고
    • Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study
    • Botticelli Investigators, Writing Committee, Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis 2008;6(8):1313-8.
    • (2008) Journal of Thrombosis and Haemostasis , vol.6 , Issue.8 , pp. 1313-1318
    • Buller, H.1    Deitchman, D.2    Prins, M.3    Segers, A.4
  • 7
    • 33746899054 scopus 로고    scopus 로고
    • The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee
    • Boudes PF. The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee. Contemporary Clinical Trials 2006;27(5):432-40.
    • (2006) Contemporary Clinical Trials , vol.27 , Issue.5 , pp. 432-440
    • Boudes, P.F.1
  • 9
    • 84890783342 scopus 로고    scopus 로고
    • Analysing data and undertaking meta-analyses
    • (editors) Higgins JPT, Green S (editors), Version 5.1.0 [updated March 2011]. The Cochrane Collaboration
    • Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
    • (2011) Cochrane Handbook for Systematic Reviews of Interventions
    • Deeks, J.J.1    Higgins, J.P.T.2    Altman, D.G.3
  • 10
    • 77950880770 scopus 로고    scopus 로고
    • Update on antithrombotic therapy: new anticoagulants
    • Eikelboom JW, Weitz JI. Update on antithrombotic therapy: new anticoagulants. Circulation 2010;121(13):1523-32.
    • (2010) Circulation , vol.121 , Issue.13 , pp. 1523-1532
    • Eikelboom, J.W.1    Weitz, J.I.2
  • 12
    • 0141636587 scopus 로고    scopus 로고
    • A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I
    • Eriksson H, Wåhlander K, Gustafsson D, Welin LT, Frison L, Schulman S, et al. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. Journal of Thrombosis and Haemostasis 2003;1(1):41-7.
    • (2003) Journal of Thrombosis and Haemostasis , vol.1 , Issue.1 , pp. 41-47
    • Eriksson, H.1    Wåhlander, K.2    Gustafsson, D.3    Welin, L.T.4    Frison, L.5    Schulman, S.6
  • 13
    • 35449007749 scopus 로고    scopus 로고
    • Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial
    • Eriksson BI, Dahl OE, Rosenecher N, Kurth AA, van Dijk CN, Frostick SP, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. Journal of Thrombosis and Haemostasis 2007;5(11):2178-85.
    • (2007) Journal of Thrombosis and Haemostasis , vol.5 , Issue.11 , pp. 2178-2185
    • Eriksson, B.I.1    Dahl, O.E.2    Rosenecher, N.3    Kurth, A.A.4    van Dijk, C.N.5    Frostick, S.P.6
  • 14
    • 57449094606 scopus 로고    scopus 로고
    • Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development
    • Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clinical Pharmacokinetics 2009;48(1):1-22.
    • (2009) Clinical Pharmacokinetics , vol.48 , Issue.1 , pp. 1-22
    • Eriksson, B.I.1    Quinlan, D.J.2    Weitz, J.I.3
  • 15
    • 84869838484 scopus 로고    scopus 로고
    • Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials
    • Fox BD, Kahn SR, Langleben D, Eisenberg MJ, Shimony A. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ 2012;345:e7498.
    • (2012) BMJ , vol.345
    • Fox, B.D.1    Kahn, S.R.2    Langleben, D.3    Eisenberg, M.J.4    Shimony, A.5
  • 17
    • 70049099036 scopus 로고    scopus 로고
    • Assessing risk of bias in included studies
    • (editors) Higgins JPT, Green S (editors), Version 5.1.0 [updated March 2011]. The Cochrane Collaboration
    • Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
    • (2011) Cochrane Handbook for Systematic Reviews of Interventions
    • Higgins, J.P.T.1    Altman, D.G.2    Sterne, J.A.C.3
  • 18
    • 34248559871 scopus 로고    scopus 로고
    • Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom
    • Huerta C, Johansson S, Wallander MA, Garcia Rodriguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Archives of Internal Medicine 2007;167(9):935-43.
    • (2007) Archives of Internal Medicine , vol.167 , Issue.9 , pp. 935-943
    • Huerta, C.1    Johansson, S.2    Wallander, M.A.3    Garcia Rodriguez, L.A.4
  • 19
    • 0028853354 scopus 로고
    • Relationship between changes in the deep venous system and the development of the postthrombotic syndrome after an acute episode of lower limb deep vein thrombosis: a one-to six-year follow-up
    • discussion 313
    • Johnson BF, Manzo RA, Bergelin RO, Strandness DE Jr. Relationship between changes in the deep venous system and the development of the postthrombotic syndrome after an acute episode of lower limb deep vein thrombosis: a one-to six-year follow-up. Journal of Vascular Surgery 1995;21(2):307-12; discussion 313.
    • (1995) Journal of Vascular Surgery , vol.21 , Issue.2 , pp. 307-312
    • Johnson, B.F.1    Manzo, R.A.2    Bergelin, R.O.3    Strandness, D.E.4
  • 20
    • 0036727049 scopus 로고    scopus 로고
    • The post-thrombotic syndrome: current knowledge, controversies and directions for future research
    • Kahn SR, Ginsberg JS. The post-thrombotic syndrome: current knowledge, controversies and directions for future research. Blood Reviews 2002;16(3):155-65.
    • (2002) Blood Reviews , vol.16 , Issue.3 , pp. 155-165
    • Kahn, S.R.1    Ginsberg, J.S.2
  • 21
    • 19944395865 scopus 로고    scopus 로고
    • Direct thrombin inhibitors: pharmacology and clinical relevance
    • Kam PC, Kaur N, Thong CL. Direct thrombin inhibitors: pharmacology and clinical relevance. Anaesthesia 2005;60(6):565-74.
    • (2005) Anaesthesia , vol.60 , Issue.6 , pp. 565-574
    • Kam, P.C.1    Kaur, N.2    Thong, C.L.3
  • 22
    • 84856802635 scopus 로고    scopus 로고
    • Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    • Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e419S-94S.
    • (2012) Chest , vol.141 , Issue.2 , pp. e419S-e494S
    • Kearon, C.1    Akl, E.A.2    Comerota, A.J.3    Prandoni, P.4    Bounameaux, H.5    Goldhaber, S.Z.6
  • 23
    • 78650931192 scopus 로고    scopus 로고
    • The direct thrombin inhibitor argatroban: a review of its use in patients with and without HIT
    • Koster A, Fischer KG, Harder S, Mertzlufft F. The direct thrombin inhibitor argatroban: a review of its use in patients with and without HIT. Biologics 2007;1(2):105-12.
    • (2007) Biologics , vol.1 , Issue.2 , pp. 105-112
    • Koster, A.1    Fischer, K.G.2    Harder, S.3    Mertzlufft, F.4
  • 25
    • 0035836541 scopus 로고    scopus 로고
    • Clinical investigation and reports. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia
    • Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, et al.for the ARG-911 Study Investigators. Clinical investigation and reports. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103(14):1838-43.
    • (2001) Circulation , vol.103 , Issue.14 , pp. 1838-1843
    • Lewis, B.E.1    Wallis, D.E.2    Berkowitz, S.D.3    Matthai, W.H.4    Fareed, J.5    Walenga, J.M.6
  • 27
    • 0027529389 scopus 로고
    • Venographic assessment of deep vein thrombosis and risk of developing post-thrombotic syndrome: a prospective study
    • Monreal M, Martorell A, Callejas JM, Valls R, Llamazares JF, Lafoz E, et al. Venographic assessment of deep vein thrombosis and risk of developing post-thrombotic syndrome: a prospective study. Journal of Internal Medicine 1993;233(3):233-8.
    • (1993) Journal of Internal Medicine , vol.233 , Issue.3 , pp. 233-238
    • Monreal, M.1    Martorell, A.2    Callejas, J.M.3    Valls, R.4    Llamazares, J.F.5    Lafoz, E.6
  • 28
    • 85041721216 scopus 로고    scopus 로고
    • Venous thromboembolic diseases: the management of thromboembolic diseases and the role of thrombophilia testing, 2012
    • (accessed 11 January 2014)
    • National Institute for Health and Care Excellence. Venous thromboembolic diseases: the management of thromboembolic diseases and the role of thrombophilia testing, 2012. guidance.nice.org.uk/CG144 (accessed 11 January 2014).
    • guidance.nice.org.uk/CG144
  • 29
    • 85041711049 scopus 로고    scopus 로고
    • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism, 2012
    • (accessed 11 January 2014)
    • National Institute of Health and Care Excellence. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism, 2012. guidance.nice.org.uk/TA261 (accessed 11 January 2014).
    • guidance.nice.org.uk/TA261
  • 30
    • 80052232522 scopus 로고    scopus 로고
    • Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial
    • Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. European Heart Journal 2011;32(22):2781-9.
    • (2011) European Heart Journal , vol.32 , Issue.22 , pp. 2781-2789
    • Oldgren, J.1    Budaj, A.2    Granger, C.B.3    Khder, Y.4    Roberts, J.5    Siegbahn, A.6
  • 33
    • 79960705415 scopus 로고    scopus 로고
    • Review Manager (RevMan)
    • 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration
    • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
    • (2012)
  • 34
    • 85041712895 scopus 로고    scopus 로고
    • Direct thrombin inhibitors or factor Xa inhibitors for the treatment of pulmonary embolism
    • Robertson L, Kesteven P. Direct thrombin inhibitors or factor Xa inhibitors for the treatment of pulmonary embolism. Cochrane Database of Systematic Reviews 2014, Issue 1.
    • (2014) Cochrane Database of Systematic Reviews , Issue.1
    • Robertson, L.1    Kesteven, P.2
  • 35
    • 0033939899 scopus 로고    scopus 로고
    • The occurrence of the post-thrombotic changes after an acute deep venous thrombosis. A prospective two-year follow-up study
    • Saarinen J, Kallio T, Lehto M, Hiltunen S, Sisto T. The occurrence of the post-thrombotic changes after an acute deep venous thrombosis. A prospective two-year follow-up study. Journal of Cardiovascular Surgery 2000;41(3):441-6.
    • (2000) Journal of Cardiovascular Surgery , vol.41 , Issue.3 , pp. 441-446
    • Saarinen, J.1    Kallio, T.2    Lehto, M.3    Hiltunen, S.4    Sisto, T.5
  • 36
    • 23044505564 scopus 로고    scopus 로고
    • Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
    • Schulman S, Kearon C, and the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis 2005;3(4):692-4.
    • (2005) Journal of Thrombosis and Haemostasis , vol.3 , Issue.4 , pp. 692-694
    • Schulman, S.1    Kearon, C.2
  • 37
    • 84862530985 scopus 로고    scopus 로고
    • A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II)
    • Schulman S, Kakkar AK, Schellong SM, Goldhaber SZ, Henry E, Mismetti P. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood 2011;118:Abstract 205.
    • (2011) Blood , vol.118
    • Schulman, S.1    Kakkar, A.K.2    Schellong, S.M.3    Goldhaber, S.Z.4    Henry, E.5    Mismetti, P.6
  • 38
    • 85041497311 scopus 로고    scopus 로고
    • Prevention and management of venous thromboembolism: a national clinical guideline, 2010
    • (accessed 11 January 2014)
    • Scottish Intercollegiate Guidelines Network. Prevention and management of venous thromboembolism: a national clinical guideline, 2010. www.sign.ac.uk/pdf/sign122.pdf (accessed 11 January 2014).
  • 39
    • 84890730197 scopus 로고    scopus 로고
    • Addressing reporting biases
    • Higgins JPT, Green S (editors), Version 5.1.0 [updated March 2011]. The Cochrane Collaboration
    • Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
    • (2011) Cochrane Handbook for Systematic Reviews of Interventions.
    • Sterne, J.A.C.1    Egger, M.2    Moher, D.3
  • 40
    • 84862585771 scopus 로고    scopus 로고
    • A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabIgatran etexilate in patients after heart valve replacement (RE-ALIGN)
    • Van de Werf F, Brueckmann M, Connolly SJ, Friedman J, Granger CB, Hartter S, et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabIgatran etexilate in patients after heart valve replacement (RE-ALIGN). American Heart Journal 2012;163(6):931-7.
    • (2012) American Heart Journal , vol.163 , Issue.6 , pp. 931-937
    • Van de Werf, F.1    Brueckmann, M.2    Connolly, S.J.3    Friedman, J.4    Granger, C.B.5    Hartter, S.6
  • 41
    • 0030281338 scopus 로고    scopus 로고
    • A 14-year study of heparin-induced thrombocytopenia
    • Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. American Journal of Medicine 1996;101(5):502-7.
    • (1996) American Journal of Medicine , vol.101 , Issue.5 , pp. 502-507
    • Warkentin, T.E.1    Kelton, J.G.2
  • 42
    • 0038344806 scopus 로고    scopus 로고
    • A novel approach to thrombin inhibition
    • Weitz JI. A novel approach to thrombin inhibition. Thrombosis Research 2003;109(Suppl 1):S17-22.
    • (2003) Thrombosis Research , vol.109 , pp. S17-S22
    • Weitz, J.I.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.